Health Highlights: Oct. 3, 2013

By on October 3, 2013

Health Highlights: Oct. 3, 2013

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:

New Gene Scan Pinpoints Causes of Rare Diseases

A newer gene sequencing technique can reveal genetic flaws that cause unexplained health problems in some patients, researchers say.

Investigators at the Baylor College of Medicine in Houston used the newer type of sequencing — just the DNA segments that contain the instructions for all the proteins required by the body — on 250 adults and children patients with mystery diseases and found that 62 of them had gene flaws, the Associated Press reported.

The findings were published online Wednesday in the New England Journal of Medicine.

The Baylor team has used the gene sequencing technique on 1,700 patients so far and found gene flaws in 1 out of 4, study leader Dr. Christine Eng told the AP.

That rate is much higher than the less comprehensive gene tests currently in use, according to Rebecca Nagy, a scientist at Ohio State University and president of the National Society of Genetic Counselors.

“For some of these conditions there could be treatments that are lifesaving,” she told the AP.


FDA Bans Arsenic Drugs Used in Animal Feed

Three of four arsenic drugs used in animal feeds have been banned by the U.S.
Food and Drug Administration.

The drugs — roxarsone, carbarsone and arsanilic acid — were added to feed for chicken, turkeys and pigs to prevent disease and promote growth. However, recent studies showed levels of arsenic in chicken that exceeded amounts that occur naturally, The New York Times reported.

Nearly four years ago, the Center for Food Safety and several other advocacy groups filed a petition seeking to ban the four drugs in animal feed.

The fourth drug, nitarsone, is the only known treatment for blackhead (histomoniasis), a disease that can kill turkeys. The FDA said it will continue to study the effects of nitarsone, The Times reported.

Leave a Reply

Your email address will not be published. Required fields are marked *